Spasmend

Quick links to important sections

Spasmend

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spasmend

Spasmend Overview: Quick Facts and Identity

Property Description
Active ingredients Acetaminophen (Paracetamol) and Mephenesin
Form Oral formulation (Tablets)
Pharmacological class Analgesic Combination
Common use Relief of pain associated with muscle tension and spasms
Origin Synthetic (Fixed-dose combination)

What is Spasmend and What Type of Drug is it?

Spasmend is a combination medicine formulated as an oral preparation, typically dispensed in tablet form, characterized by the synergistic action of two distinct active components. It is classified as an analgesic combination, indicating that the medicine is designed to simultaneously address pain and associated symptoms. The drug is synthetic, and its structure involves pairing a non-narcotic analgesic with a centrally acting muscle relaxant. This specific fixed-dose combination is positioned for adult patients (18 years and older), distinguishing it from single-agent formulations.

Active Ingredients: The Composition of Spasmend

The efficacy of Spasmend relies on the specific combination of two active ingredients: Acetaminophen (Paracetamol) and Mephenesin. Acetaminophen is an established analgesic and antipyretic agent, supporting its core role in pain relief. The second substance, Mephenesin, is a skeletal muscle relaxant. This combination is recognized for its targeted relief in cases where pain co-exists with muscle hyperactivity, often managing discomfort stemming from common muscle tension.

What is the General Therapeutic Purpose of Spasmend?

The primary therapeutic purpose of Spasmend is the integrated relief of generalised pain associated with tension. The dual-action mechanism is intentionally synergistic: the Acetaminophen component helps reduce the perception of discomfort by elevating the body's overall pain threshold. Concurrently, the Mephenesin component acts to lessen the intensity of involuntary muscle contractions or muscle spasms. This integrated therapeutic design defines its core utility for symptomatic relief when the discomfort is complicated by muscle hypertonicity or rigidity.

Regulatory References

  1. SAHPRA Repository
  2. National Institutes of Health (NIH) MedlinePlus

What side effects are possible with Spasmend?

Possible Side Effects and Safety Information

The safety profile for Spasmend, a combination of Acetaminophen (Paracetamol) and Mephenesin, is formally structured according to regulatory standards to classify potential adverse reactions and define safety limitations. The documentation of adverse reactions often utilizes a Frequency Unknown classification, indicating that the incidence cannot be estimated accurately from the available post-marketing data.


Documented Adverse Reaction Categories

Adverse effects are grouped by System-Organ-Class (SOC), providing a formal overview of affected physiological systems. Reactions documented include effects on the Nervous System (e.g., drowsiness, dizziness, lassitude), Gastrointestinal Disorders (nausea, vomiting, abdominal pain), and the Skin and Subcutaneous Tissue (various rashes and hypersensitivity reactions). Blood disorders such as neutropenia and anaemia are also listed in the regulatory documents.


Serious Safety Risks and Limitations

Regulatory labels document serious adverse reactions associated primarily with the Acetaminophen component. These include the risk of Severe Liver Damage (Hepatotoxicity), which is strongly associated with exceeding recommended doses or chronic, high-dose exposure. Rare but severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome, are also noted in official warnings.


Population-Specific Constraints

The medicine is formally contraindicated in patients with known impaired kidney and liver function. This restriction defines critical boundaries for use based on pre-existing physiological conditions. Due to the potential for CNS effects like drowsiness, the label includes cautions regarding the performance of tasks requiring mental alertness, particularly during the initial period of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that an overdose of Spasmend (Mephenesin/Paracetamol) is a serious medical emergency, requiring immediate attention even if symptoms are not present.

Documented Manifestations and Severe Outcomes

Symptoms in the initial phase (within 24 hours) may be non-specific, including nausea, vomiting, pallor, and anorexia (Paracetamol component). Gross overdosage can lead to two distinct, life-threatening complications:

  • Hepatotoxicity: The primary risk is delayed, progressive liver damage that can result in hepatic encephalopathy, coma, and death. Severe liver failure may be evident only 12 to 48 hours or later after ingestion.
  • CNS/Respiratory Depression: The Mephenesin component can cause severe hypotonia, CNS depression, and respiratory paralysis, potentially requiring support to maintain breathing.

Mandatory Emergency Actions

The most critical instruction from regulatory bodies is to immediately contact a doctor, hospital, or Poison Centre following any suspected overdose, regardless of whether the individual feels well or is exhibiting symptoms. A delay in starting treatment, particularly the administration of the antidote, can lead to irreversible damage.

Antidote Information: N-acetylcysteine is the specific antidote required for the Paracetamol component and must be administered promptly. Treatment protocols typically require determining the plasma Paracetamol level four hours post-ingestion to guide ongoing therapy.

Monitoring: Hospital observation and monitoring of hepatic function (e.g., liver enzymes) and renal function are essential in managing overdose cases.

Therapeutic Uses of Spasmend

What Spasmend Treats: Main Uses and Benefits

Spasmend is commonly used in situations involving generalised and symptomatic pain associated with tension in adults. The medicine is relevant in contexts marked by increased discomfort or tension, where additional symptomatic support is appropriate.

The core therapeutic domains include managing musculoskeletal pain, general aches, and addressing symptom clusters such as involuntary muscle spasms, rigidity, and noticeable muscle stiffness. This medicine is often used during phases when symptoms become more noticeable, offering supportive symptomatic relief.

“It is relevant in conditions characterized by periods of heightened symptoms where the primary discomfort is linked to increased physiological or muscular activity.”


Quick Fact: Supportive Relief for Muscular Symptoms

Spasmend helps address symptom clusters that create noticeable physiological strain and heightened symptoms, offering symptomatic relief that may assist with maintaining functional stability during symptomatic phases.

Regulatory References

  1. SAHPRA Repository

Eligibility and Restrictions for Use

The eligibility for Spasmend is defined by official regulatory documentation, establishing specific populations for whom use is allowed, restricted, or prohibited.

Eligibility Scope

Classification Population Rule (Official Regulatory Statement)
Approved Use Use is established only for Adults (18 years and older).
Contraindicated Prohibited in patients with Impaired kidney and liver function.
Contraindicated Prohibited due to Hypersensitivity to paracetamol, mephenesin, or any excipients.

Regulatory Restrictions

The medicine is not recommended for children and adolescents younger than 18 years old as its safety and efficacy in this age group have not been established. Use is restricted and requires special care in patients with other forms of impaired renal or hepatic function. Conditional use also applies to patients with certain underlying conditions, including chronic alcoholism, chronic liver disease, AIDS, or malnutrition, due to the increased susceptibility to toxicity from the paracetamol component. The product label also states that safety affecting fertility, pregnancy, and lactation has not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Spasmend’s interaction profile is defined by restrictions and cautions related to its active components, Acetaminophen (Paracetamol) and Mephenesin, as documented in official regulatory labeling.

Formal Restrictions and Prohibitions

Co-administration with any other medicinal product containing acetaminophen or paracetamol is strictly contraindicated. This is a mandated prohibition to prevent exceeding safe dosage limits and avoid the risk of severe liver damage. A formal warning exists regarding the risk of severe liver damage if the medicine is used concurrently with the consumption of three or more alcoholic drinks daily.

Documented Drug Interactions

The Mephenesin component may enhance the effects of other Central Nervous System (CNS) depressants, such as barbiturates and opioids, which is an officially noted pharmacodynamic interaction. Concomitant use with the anticoagulant sodium warfarin may cause an officially observed increase in International Normalized Ratio (INR), indicating an alteration of the anticoagulant’s plasma effect. Furthermore, drugs that induce liver microsomal oxidation, such as certain barbiturates, can officially increase susceptibility to paracetamol toxicity.

Population-Specific Notes

Official regulatory cautions note that susceptibility to paracetamol toxicity is increased in populations with chronic alcoholism or chronic liver disease.

Mechanism of Action

Spasmend is a fixed-dose combination product containing mephenesin and paracetamol (acetaminophen), each modulating distinct biological targets.

Mephenesin functions as a centrally acting muscle relaxant, primarily targeting the central nervous system (CNS), particularly the spinal cord. Mechanistically, mephenesin is proposed to act as a weak non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor complex, a key ionotropic receptor for glutamate. This interaction modulates excitatory neurotransmission, leading to an overall reduction in the excitability of spinal interneurons. The resultant decrease in polysynaptic reflex activity contributes to systemic skeletal muscle relaxation.

Paracetamol exerts its action primarily within the CNS. It is considered a weak inhibitor of prostaglandin (PG) synthesis. This effect is hypothesized to occur via selective inhibition of the cyclooxygenase-2 (COX-2) enzyme in the brain, particularly when local arachidonic acid concentrations are low. Alternatively, a metabolite, N-acylphenolamine (AM404), is thought to act as an agonist at the transient receptor potential vanilloid 1 (TRPV1) receptor, and/or to influence descending serotonergic pain pathways in the spinal dorsal horn. The consequence of these cellular interactions is a systemic modulation of nociceptive signaling.

Dosage and Administration Information

Spasmend is an oral fixed-dose combination medicine administered in tablet form. Its use is defined by guidelines that govern the route, dosage frequency, and duration of administration.

Administration Guidelines

The established regimen is designated for Adults aged 18 years and older only, as the safety and efficacy of the combination have not been established for younger populations. The administration pattern involves taking one or two tablets as a single dose. To maintain proper dosage intervals, this administration must be separated by a minimum time of four hours.

Strict constraints are placed on both daily and long-term consumption. The total intake must not exceed eight tablets within any 24-hour period. Furthermore, continuous use of the medication is advised not to exceed ten days without consultation for clinical reassessment. The medicine may be taken without specific regard to food, as instructions do not specify a relationship with meals. These constraints define the procedural parameters for the medicine's use.

Classification Detail
Route Oral (Tablets)
Dosing Frequency Every four hours
Maximum Duration 10 days continuous use
Protocol Basis Standard Protocol

Recent Clinical Evidence

Research evidence / Overview of studies for Spasmend

Evidence for Generalized Pain Associated with Muscle Tension and Spasm

Research has examined the components of Spasmend to understand how they contribute to the broader evidence landscape for conditions involving pain and muscle tension. The specific fixed-dose combination of Acetaminophen and Mephenesin was studied for its use in conditions characterized by fluctuating or episodic manifestations of musculoskeletal pain. Researchers primarily focused on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

The scientific literature reports that most of the research, including large-scale systematic reviews and meta-analyses, focuses on the single analgesic component (Acetaminophen). These large studies described patterns related to changes in pain intensity in certain acute pain settings, while showing variable outcomes in some chronic musculoskeletal conditions. Specific controlled trials evaluating the combination of Acetaminophen and Mephenesin are few in the published scientific literature. The existing data described patterns observed in the studies related to both pain and muscle stiffness metrics.


Key Areas of Research Uncertainty

A primary limitation in the evidence base is that comparative evidence is lacking for the specific combination against a placebo or its individual components. The evidence quality varies across studies, leading to some uncertainty when extrapolating findings across different pain conditions. The body of evidence for the specific combination is considered limited, while research for the single analgesic component in specific pain conditions is more extensive and consistent.

Additionally, follow-up durations were limited in many controlled trials, contributing to uncertainty regarding the sustained nature of the reported symptom changes. Research has not fully established or characterized the patterns of change for patients who were observed in studies extending over many months or years. This means that while studies help show what has been observed so far, research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Spasmend PI (Package Insert) - Adcock Ingram
  2. Acetaminophen (NIH/MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Spasmend (FAQ)


Q: Is Spasmend the same class of medicine as a general pain reliever?

Official regulatory information classifies Spasmend as an analgesic combination. This means the medicine contains both a recognized analgesic (pain-relieving) component and a centrally acting muscle relaxant component. Its dual composition means it is intended to address both pain and associated muscle tension.


Q: Is it typically safe to drink a moderate amount of alcohol while using Spasmend?

Official product warnings advise caution when consuming alcohol while taking this medicine. A formal warning exists regarding the risk of severe liver damage if Spasmend is used concurrently with the consumption of three or more alcoholic drinks daily. This defined threshold highlights a specific safety constraint noted in the product information.


Q: What is the difference between an antispasmodic like Spasmend and a skeletal muscle relaxant?

Spasmend is intended to relieve pain associated with involuntary muscle contractions, or spasms. Its active ingredient, Mephenesin, is categorized as a skeletal muscle relaxant in regulatory documents. These terms describe the medicine's mechanism of action, which works in the central nervous system to reduce muscle tension associated with muscle hypertonicity.


Q: What did the clinical trials say about long-term use of Spasmend?

Studies and official information indicate that follow-up durations were limited in the controlled trials conducted for this combination medicine. Consequently, research has not fully characterized the patterns of change or the sustained nature of the effects for patients observed over many months or years.


Q: Are severe allergic reactions to Spasmend a common or rare concern?

Official documentation lists rare but severe skin reactions, such as SCARs, as a potential risk. Other types of hypersensitivity reactions, like rashes, are also documented. Many adverse events are listed with a Frequency Unknown classification, indicating that their exact incidence rate cannot be accurately estimated from available data.


Q: What does the term contraindications mean in relation to taking Spasmend?

A contraindication describes a specific health condition or factor that officially prohibits the use of a medicine. For Spasmend, official documents state it is contraindicated, for example, if a patient has known impaired kidney or liver function or a hypersensitivity to its ingredients. This restriction defines critical boundaries for use.


Q: What common over-the-counter pain relievers or cold medicines interact with Spasmend?

Official regulatory authorities strictly contraindicate the co-administration of Spasmend with any other medicinal product containing acetaminophen or paracetamol. This is a mandatory prohibition noted in the product information to help manage the risk of exceeding safe dosage limits and liver damage.


Q: Do specific dietary restrictions apply when taking Spasmend?

Official label instructions state the medicine may be taken without specific regard to food. However, a formal warning exists regarding the consumption of three or more alcoholic drinks daily due to the risk of severe liver damage.


Q: Why do some patient reports mention feelings of anxiety or restlessness with Spasmend?

Official documentation lists adverse effects in groups, such as the Nervous System. Documented reactions in this category include drowsiness, dizziness, and lassitude. The specific effects of anxiety or restlessness are not explicitly listed in the official adverse reaction documentation provided by regulatory sources.


Q: How quickly can a person usually expect to feel the effects of Spasmend?

Regulatory documents typically contain pharmacokinetic data that describes the time required for the active ingredients to reach their maximum concentration in the bloodstream. This information provides an indication of the expected onset of action for the medicine.


Q: How long does one dose of Spasmend typically stay active in the body?

Official documentation includes pharmacokinetic data that describes the half-life of the active ingredients. The half-life indicates the time required for the amount of medicine in the body to decrease by half, providing general context for how long a dose remains in the system.


Q: Does Spasmend have a risk of becoming habit-forming or leading to physical dependence?

Official drug labels typically include information in the warnings and precautions sections that addresses potential risks associated with dependence, abuse, or tolerance. This information is standardized and available in regulatory documents.


Q: Is Spasmend considered a controlled substance?

The controlled substance status of a medicine is a mandatory designation determined by regulatory agencies. Official labeling includes a section that classifies the drug based on its potential for abuse or dependence under schedules defined by the governing regulatory body.


Q: What is the general procedure if a person forgets to take their usual dose of Spasmend?

Patient information materials published by regulatory bodies typically provide general, non-personalized guidance for consumers on the procedure to follow in the event a person forgets to take a dose of the medicine.


Q: Is there a described withdrawal period when stopping the use of Spasmend?

Regulatory safety documentation includes information on what has been observed regarding the effects of stopping the medicine. This documentation provides details about potential discontinuation effects or withdrawal symptoms.


Q: Are there any documented mental health side effects associated with Spasmend?

Adverse effects are formally grouped by System-Organ-Class (SOC), which includes a specific category for Psychiatric Disorders. Any documented mental health side effects, such as mood changes, would be officially listed within this category in the regulatory documents.


Q: Is it possible for the effects of Spasmend to lessen over time (tolerance)?

Official drug labeling addresses potential risks associated with tolerance, which is the possibility for the medicine's effects to decrease with continuous use. This topic is covered in the warnings and precautions sections of the regulatory documents.


Q: Can a person with diagnosed high blood pressure safely take Spasmend?

Regulatory cautions and restrictions define specific conditions that require special care or prohibit the use of this medicine. Any necessary precautions related to underlying conditions, such as high blood pressure, would be formally documented in the warnings and eligibility sections of the official label.


Q: Does Spasmend contain gluten, lactose, or other common dietary allergens?

Regulatory documents include a full list of all inactive ingredients (excipients) used in the formulation. This information specifies the presence or absence of substances such as lactose or gluten in the tablet.


Q: What should be done if a person experiences a mild, non-severe side effect while on Spasmend?

Patient information materials typically contain general guidance on the monitoring or reporting of adverse effects. They also offer general, non-directive information on when to seek professional advice for symptoms experienced while using the medicine.


Q: Is Spasmend a medicine that always requires a prescription?

The official regulatory label clearly designates the medicine's status as either a prescription product or one available over-the-counter. This designation is based on the safety and administration constraints defined by the governing authority.


Q: Does Spasmend affect the results of routine lab tests, like blood work?

Official labeling addresses known interactions between the medicine and diagnostic procedures. Any scientifically established interference with routine laboratory tests, such as blood work, would be formally documented in the warnings and precautions section.


Q: Can Spasmend be used with other prescribed spasm-relieving treatments?

Official documentation notes that the Mephenesin component may enhance the effects of other Central Nervous System (CNS) depressants. This is an officially noted pharmacodynamic interaction that defines a potential safety risk when combining with similar agents.


Q: Can people with diabetes safely use Spasmend?

Regulatory cautions and restrictions define specific conditions that may affect the use of this medicine. Any necessary precautions related to underlying chronic metabolic conditions, such as diabetes, would be formally documented in the warnings and eligibility sections of the official label.


How should Spasmend be stored and disposed of?

How to Store and Dispose of Spasmend

Official Storage Conditions

Spasmend tablets must be stored in a cool, dry place at or below 30 C. To maintain the stability of the medicine, it must not be stored in high-humidity areas, such as bathrooms. The product should be kept in its original outer carton and the blister pack must not be removed until the tablet is required for use. All tablets must be stored out of the sight and out of reach of children.

Stability and Expiry

The tablets should not be used past the expiry date stated on the packaging. The medicine’s official shelf life is typically 24 months, provided the correct storage temperature is maintained.

Disposal Instructions

To ensure proper pharmaceutical waste management, any unused or expired Spasmend tablets should be returned to a pharmacist or designated take-back point. This process ensures the medicine is destroyed according to local regulatory and municipal guidelines, preventing environmental contamination and ensuring the product cannot be recovered.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spasmend found in:

A-Z Index: